Bioinformatics Analysis of Quantitative PCR and Reverse Transcription PCR in Detecting HCV RNA

Author(s): Wei Liu, Xiwen Jiang, Yue Liu, Qingsong Ma*.

Journal Name: Current Bioinformatics

Volume 14 , Issue 5 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Objective: This research aimed to make comparisons of sensitivity and specificity between Quantitative real Time Polymerase Chain Reaction (Q-PCR) and Reverse Transcription PCR (RT-PCR) in detecting the ribonucleic acid (RNA) expression levels of Hepatitis C Virus (HCV).

Methods: 121 patients suffering from hepatitis C and 98 healthy participants with normal liver functions were identified. The venous blood collections were carried out, were subjected to detect the expression levels of HCV RNA via Q-PCR and RT-PCR. And then, the data obtained from these above two detection methods were compared, including the sensitivity and specificity.

Results: In terms of Q-PCR, the positive rate of HCV RNA was 72.16%, which was significantly higher when compared with 55.26% of RT-PCR. After statistical analysis, the difference between them was statistically significant (P<0.05). Among the healthy participants, 4 cases were false positive by means of RT-PCR, there was the possibility of missed diagnosis when the samples were evaluated by Q-PCR.

Conclusion: The Q-PCR detection technology performed well in testing HCV, with pretty high sensitivity and specificity. Nevertheless, the false negative results obtained from Q-PCR could not be avoided. In clinical practice, these above two detection methods should be referred to, in order to avoid missed diagnosis.

Keywords: Hepatitis C virus, ribonucleic acid, quantitative real time polymerase chain reaction, reverse transcription polymerase chain reaction, liver cirrhosis, hepatocellular carcinoma.

[1]
Uchiyama N, Kamakura H, Masada S, et al. Chemical analysis of counterfeit hepatitis C drug found in Japan. Yakugaku Zasshi 2017; 137(10): 1265-76.
[2]
Ladino M, Pedraza F, Roth D. Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease. World J Hepatol 2017; 9(19): 833-9.
[3]
Jeffrey AW, Huang Y, de Boer WB, et al. Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome. World J Hepatol 2017; 9(19): 850-6.
[4]
Muñoz de Rueda P, Fuentes Rodríguez JM, Quiles Pérez R, et al. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment. World J Gastroenterol 2017; 23(25): 4538-47.
[5]
Grewal P, Sanghera R. Hepatitis B and C viruses and biologics. Skin Therapy Lett 2017; 22(4): 7-9.
[6]
Xu HT, Colby-Germinario SP, Hassounah SA, et al. Evaluation of Sofosbuvir (β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine) as an inhibitor of dengue virus replication. Sci Rep 2017; 7(1): 6345.
[7]
Wang Z, Gao Y, Zhang C, et al. Quinolinate phosphoribosyl-transferase is an antiviral host factor against hepatitis C virus infection. Sci Rep 2017; 7(1): 5876.
[8]
Tanaka Y, Iwasaki M, Murata-Hirai K, et al. Anti-tumor activity and immunotherapeutic potential of a bisphosphonate prodrug. Sci Rep 2017; 7(1): 5987.
[9]
Stelma F, de Niet A, Sinnige MJ, et al. Human intrahepatic CD69+ CD8+ T cells have a tissue resident memory T cell phenotype with reduced cytolytic capacity. Sci Rep 2017; 7(1): 6172.
[10]
Madhvi A, Hingane S, Srivastav R, et al. A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound. Sci Rep 2017; 7(1): 5816.
[11]
Luong TTD, Tran GVQ, Shin DJ, Lim YS, Hwang SB, Hepatitis C. hepatitis C virus exploits death receptor 6-mediated signaling pathway to facilitate viral propagation. Sci Rep 2017; 7(1): 6445.
[12]
Chen J, Zhang Z, Wang N, et al. Role of HDAC9-FoxO1 axis in the transcriptional program associated with hepatic gluconeo-genesis. Sci Rep 2017; 7(1): 6102.
[13]
Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Phatharacharukul P, Ungprasert P. Hepatitis C virus infection and risk of osteoporosis: A meta-analysis. Saudi J Gastroenterol 2017; 23(4): 216-21.
[14]
Al-Busafi SA, Omar H. Towards supporting greater and lower cost access to direct acting antiviral treatment for hepatitis C for all patients. Saudi J Gastroenterol 2017; 23(4): 263-4.
[15]
WHO Guidelines on Hepatitis B and C Testing 2017, 2017.
[16]
Huang MY, Chung CH, Chang WK, et al. The role of thia-zolidinediones in hepatocellular carcinoma risk reduction: A population-based cohort study in Taiwan. Am J Cancer Res 2017; 7(7): 1606-16.
[17]
Vieira-Castro ACM, Oliveira LCM. Impact of alcohol consumption among patients in hepatitis C virus treatment. Arq Gastroenterol 2017; 54(3): 232-7.
[18]
Gorzoni ML, Aguado MRV, Pires SL, Faria LFC. Compulsory notification at skilled nursing facilities. Rev Assoc Med Bras (1992) 2017. 63(5): 447-51.
[19]
Stelzl E, Haas B, Bauer B, et al. First identification of a recombinant form of hepatitis C virus in Austrian patients by full-genome next generation sequencing. PLoS One 2017; 12(7): e0181273.
[20]
Sabet S, George MA, El-Shorbagy HM, et al. Gelatin nanoparticles enhance delivery of hepatitis C virus recombinant NS2 gene. PLoS One 2017; 12(7): e0181723.
[21]
Russelli G, Pizzillo P, Iannolo G, et al. HCV replication in gastrointestinal mucosa: Potential extra-hepatic viral reservoir and possible role in HCV infection recurrence after liver transplantation. PLoS One 2017; 12(7): e0181683.
[22]
Merdan M, Bekiryazici Z, Kesemen T, Khaniyev T. Deterministic stability and random behavior of a Hepatitis C model. PLoS One 2017; 12(7): e0181571.
[23]
Hughes MG Jr, Tucker WW, Reddy S, et al. Rate of hepatitis C viral clearance by human livers in human patients: Liver transplantation modeling primary infection and implications for studying entry inhibition. PLoS One 2017; 12(7): e0180719.
[24]
Liu Y, Liu Y, Zou X, Chen W, Ling L. Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study. BMJ Open 2017; 7(7): e015524.
[25]
Lu M, Chacra W, Rabin D, et al. Validity of an automated algo-rithm using diagnosis and procedure codes to identify decom-pensated cirrhosis using electronic health records. Clin Epidemiol 2017; 9: 369-76.
[26]
McEwan P, Webster S, Ward T, Brenner M, Kalsekar A, Yuan Y. Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus. Cost Eff Resour Alloc 2017; 15: 15.
[27]
Bernuth S, Grimm D, Vollmar J, et al. Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort. Drug Des Devel Ther 2017; 11: 2131-8.
[28]
Rychlik W, Spencer WJ, Rhoads RE. Optimization of the annealing temperature for DNA amplification in vitro. Nucleic Acids Res 1990; 18(21): 6409-12.
[29]
Joseph S, David WR. Molecular cloning: A Laboratory. Manual 3rd ed.. 2001.
[30]
Ferri C, Colaci M, Fallahi P, Ferrari SM, Antonelli A, Giuggioli D. Thyroid involvement in hepatitis C virus-infected patients with/without mixed cryoglobulinemia. Front Endocrinol 2017; 8: 159.
[31]
Son K, Nguyen TTT, Choi JW, et al. Rad51 Interacts with Non-structural 3 protein of hepatitis C Virus and regulates viral production. Front Microbiol 2017; 8: 1249.
[32]
Jovanovic MR, Miljatovic A, Puskas L, Kapor S, Puskas DL. Does the strategy of risk group testing for hepatitis C hit the target? Front Pharmacol 2017; 8: 437.
[33]
Des Jarlais DC. Harm reduction in the USA: the research perspective and an archive to David Purchase. Harm Reduct J 2017; 14(1): 51.
[34]
Alouani I, Fihmi N, Zizi N, Dikhaye S. Dermatomyositis revealing both a metastatic linitis plastica and hepatitis C virus infection. Indian J Dermatol Venereol Leprol 2017; 83(5): 606-9.
[35]
Ribeiro Barbosa J, Sousa Bezerra C, Carvalho-Costa FA, et al. Cross-sectional study to determine the prevalence of hepatitis B and C virus infection in high risk groups in the northeast region of brazil. Int J Environ Res Public Health 2017; 14(7): 14.
[36]
Bruno G, Saracino A, Scudeller L, et al. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? Int J Infect Dis 2017; 62: 64-71.
[37]
Agrawal B, Singh S, Gupta N, Li W, Vedi S, Kumar R. Unsolved puzzles surrounding HCV immunity: Heterologous immunity adds another dimension. Int J Mol Sci 2017; 18(8): 18.
[38]
Shaukat AA, Zar A, Zuhaid M, Afridi SS. Correlation of deviance in arterial oxygenation with severity of chronic liver disease. J Ayub Med Coll Abbottabad 2016; 28(2): 331-6.
[39]
Pirro M, Bianconi V, Francisci D, et al. Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: A detrimental interaction to increase viral infectivity and disrupt lipid metabolism. J Cell Mol Med 2017; 21(12): 3150-61.
[40]
Kah J, Koh S, Volz T, et al. Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection. J Clin Invest 2017; 127(8): 3177-88.
[41]
Soto-Ramirez LE. World hepatitis day. Fighting hepatitis C in Latin America and the Caribbean; an urgent call. J Int AIDS Soc 2017; 20(1): 22183.
[42]
Ito M, Sun S, Fukuhara T, et al. Development of hepatoma-derived, bidirectional oval-like cells as a model to study host interactions with hepatitis C virus during differentiation. Oncotarget 2017; 8(33): 53899-915.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 14
ISSUE: 5
Year: 2019
Page: [400 - 405]
Pages: 6
DOI: 10.2174/1574893613666180703103328
Price: $58

Article Metrics

PDF: 17
HTML: 2